NANOBIOTIX Provides Business Update and Reports Full Year 20

New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data

Related Keywords

China , Germany , New York , United States , Paris , France General , France , Texas , Massachusetts , Cambridge , Cambridgeshire , United Kingdom , Canada , Spain , Brandon Owens , Kate Mcneil , Porter Novelli , Pierre Louis Germain , Dan Childs , Bart Van Rhijn , Exchange Commission On , University Of Texas Md Anderson Cancer Center , Linkedin , French Financial Markets Authority Autorit , Twitter , International Journal Of Radiation Oncology , Drug Administration , Nanobiotix Communications , Md Anderson Cancer Center , Nasdaq , Development Rd Expenses , Given The Company , Pharmaengine Inc , Euronext , Expansion Study , Overall Survival , Laurent Levy , Pipeline Status , Head Neck Cancer , Local Control , Single Agent Activated , American Society , Radiation Oncology , Advanced Cancers , Priming Immune Response , World Class Partners , Validate Tumor Agnostic , Combination Agnostic Therapeutic Profile , Cancer Center , International Journal , Red Journal , Cash Equivalents , Financial Update , General Meeting , Year Corporate , United States Food , Fast Track , Nasdaq Global Select Market , New York City , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , French Financial Markets Authority , Investor Relations , Nanobiotix , Rovides , Business , Update , Reports , Bull , Ear , 021 , Financial , Results ,